
Abstract This phase 1, randomized, open‐label, single‐dose, parallel‐group study aimed to describe the pharmacokinetic (PK) comparability and safety of canakinumab administered as a single 200 mg subcutaneous injection via pre‐filled syringes assembled within a needle safety device (PFS‐NSD) by HCP and auto‐injector (AI) by subject self‐administration versus two injections of 150 + 50 mg via PFS‐NSD by HCP. Healthy adults (18–55 years) were allocated to three arms: canakinumab 150 + 50 mg (PFS‐NSD; n = 78), canakinumab 200 mg (AI; n = 76), and canakinumab 200 mg (PFS‐NSD; n = 76). Multiplicity was addressed as two tests were compared with the same reference. Primary PK parameters were comparable across arms. The geometric mean ratios and 95% CI values of AUC inf , AUC last , and C max were within bioequivalence limits of 0.80‐1.25 for both comparisons: (a) canakinumab 200 mg AI versus canakinumab 150 + 50 mg PFS‐NSD and (b) canakinumab 200 mg PFS‐NSD versus canakinumab 150 + 50 mg PFS‐NSD. Median T max was comparable: 7, 9, and 7 days for canakinumab 150 + 50 mg PFS‐NSD, 200 mg AI, and 200 mg PFS‐NSD, respectively. Exploratory post‐hoc analyses, assessing the impact of pause during the pandemic (N = 131 subjects recruited pre‐pandemic) and evaluating partial AUC 4weeks , suggested similar results. Canakinumab was well‐tolerated, and no treatment‐induced immunogenicity was observed.
Abstract This was a first‐in‐human, single‐center, Phase 1 study of izicopan (formerly INF904), a potent oral, second‐generation small molecule antagonist of C5aR1, in healthy adults. Participants were randomized to a single oral dose of izicopan 3–240 mg or matched placebo (single ascending dose [SAD]), or multiple doses of izicopan 30 mg once daily (QD), 30 or 90 mg twice daily (BID), or matched placebo, for 14 days (multiple ascending dose [MAD]). In the SAD study, izicopan plasma concentration increased with dose from 3 to 240 mg; the mean maximum plasma concentration (C max ) was 21.5–1216.0 ng/mL, reached at a median time (t max ) of 3.5–6.0 h, followed by a biphasic decline. In the MAD study, a steady state appeared to have been reached within 14 days, and AUC 0‐tau exhibited an accumulation ratio of ∼2‐fold following BID dosing, suggesting an effective half‐life of ∼12 h. In an ex vivo whole blood PD assay, izicopan resulted in >90% blockade of CD11b upregulation by recombinant human C5a across almost all dose cohorts from Days 2–15. Adverse events were mild or moderate in severity. In conclusion, izicopan was safe across all single and multiple doses evaluated. Sufficient izicopan exposure was achieved rapidly to exert >90% blockade of C5a‐C5aR1 signaling.
Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low-molecular-weight inhibitor of the coronavirus main protease (Mpro). This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo-controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open-label, three-period, six sequence, randomized, cross-over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose-dependent or dose-limiting adverse effects. EGT710 was rapidly absorbed (median Tmax 2.0 h), showed sub-proportional AUC and Cmax increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased Cmax by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.
Enzalutamide is an oral second-generation androgen receptor inhibitor used for advanced prostate cancer. This study evaluated the pharmacokinetics (PK), bioequivalence (BE), and safety of a newly developed generic enzalutamide soft capsule (test) compared with the reference product (XTANDI) in healthy Chinese adults under fasting and fed conditions. A single-center, randomized, open-label, two-period, two-sequence, crossover study was conducted in 72 male participants (36 fasting and 36 fed). Each participant received a single 40-mg dose of test or reference formulation, separated by a 34-day washout. Blood samples were collected up to 72 h post-dose. PK parameters (Cmax and AUC0-72 h) were calculated using non-compartmental analysis. BE was assessed by 90% confidence intervals (CIs) of geometric mean ratios (GMRs). Safety was monitored throughout the study. In both fasting and fed conditions, the 90% CIs of GMRs for Cmax and AUC0-72 h were within the predefined 80%-125% BE range. Both formulations exhibited a favorable single-dose safety profile, with no serious adverse events reported. The test enzalutamide soft capsule is bioequivalent to the reference product in healthy Chinese volunteers, demonstrating similar PK profiles and safety. This study provides population-specific PK evidence supporting the clinical use of the generic formulation in China.